The Genevium Research Hub is a peptide research reference library organized into three focused domains: Metabolic, Skin & Cosmetic, and Healing & Sleep. Each domain covers compound mechanisms, comparative research, and the methodology considerations that govern rigorous laboratory work.
Articles published in the Hub follow strict Research Use Only framing and are written for laboratory research, literature review, and methodology reference. Compounds discussed include both research peptides available in the Genevium product line and compounds covered for completeness of the research landscape.
Cosmetic peptide research, copper peptide signaling, and dermal biology including signal peptides, neurotransmitter-inhibiting peptides, and carrier peptides.
Methodology reference on the freeze-drying process applied to peptides, the rationale for lyophilization, storage temperatures and shelf life expectations, and the visual and analytical quality indicators researchers use to assess lyophilized material before reconstitution.
A research framework organizing skin-active peptides by mechanism category. Covers signal peptides, neurotransmitter-inhibiting peptides, carrier and anti-inflammatory peptides, model systems from 2D fibroblast culture to ex vivo skin explants, and methodology and quality standards.
A research framework for the recovery peptide landscape covering tissue-repair peptides (BPC-157, TB-500), immunomodulatory peptides (KPV, Thymosin Alpha-1, LL-37), and sleep-and-restoration peptides (DSIP, Epitalon, Pinealon). Includes methodology considerations and quality standards.
Mechanism of action research on Tirzepatide (LY3298176), the dual agonist of GIP and GLP-1 receptors. Covers imbalanced potency, biased signaling at the GLP-1 receptor, integrated metabolic pharmacology, and comparative incretin research.
Mechanism of action research on Retatrutide (LY3437943), the triple agonist of GIP, GLP-1, and glucagon receptors. Covers receptor potency balance, energy expenditure pharmacology, and mitochondrial biogenesis signaling architecture.
Comparative research on BPC-157 and TB-500 covering structural origins, proposed mechanisms across angiogenic and actin-cytoskeletal pathways, areas of mechanistic overlap and distinction, and methodology considerations for combination peptide research.
